February 16, 2018 09:07 AM EST
Peer Review

Ex-Ax­o­vant COO Mar­i­on Mc­Court lands at Re­gen­eron; GT Bio­phar­ma el­e­vates Shawn Cross to CEO in ex­ec reshuf­fle

Amber Tong

→ While our eyes were fixed on CEO David Hung’s de­par­ture from strug­gling Ax­o­vant, COO Mar­i­on Mc­Court al­so qui­et­ly jumped ship — to Re­gen­eron $REGN. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times